PDCD1 and neoplasm: Adequate analysis of the mechanisms underlying the action of tumor-associated macrophages in CRC and complementary macrophage immunotherapy with immune checkpoint inhibitors (CTLA-4 antibodies, anti-PD-1 and PD-L1) can strengthen the treatment outcome (166).